कंपनी का अवलोकन
Context Therapeutics Inc. operates as a biopharmaceutical entity dedicated to the development of therapeutic products specifically designed for the treatment of solid tumors. The company functions within the healthcare sector, with its specific operational niche located in the biotechnology industry, which typically involves high levels of research and development investment. As of the latest data, the entity has a market capitalization of $237.97M and employs approximately 15 individuals. The market cap figure of $237.97M indicates a small-cap status, suggesting the company is in an early to mid-stage of development where valuation is often driven by potential pipeline assets rather than current profitability. While the available financial data does not disclose annual revenue, the combination of a market cap in the low hundreds of millions and a minimal employee count highlights the resource-intensive nature of biotechnology firms that rely heavily on cash reserves to fund clinical trials and manufacturing processes. This scale reflects a company that is likely focused on proving the efficacy of its lead program candidates before achieving significant commercial sales.
वित्तीय स्वास्थ्य
The financial performance of Context Therapeutics Inc. shows a Net Income of $-36,123,616 and an EBITDA of $-39,686,380 over the trailing twelve-month period, while Revenue figures are not currently reported in the available data. The substantial gap between the reported net income and the negative EBITDA reveals a cost structure heavily impacted by non-operating expenses or interest costs, as the operating cash generation is significantly different from the accounting net loss. The company reports a Free Cash Flow of $-19,126,216, which indicates a continuous burn rate typical for biotechnology firms in the pre-revenue phase, limiting immediate financial flexibility but necessary for long-term asset creation. All three margin metrics—Gross Margin, Operating Margin, and Profit Margin—are recorded at 0.0%, which signifies that the company has not yet generated positive gross profit or operating income, a common characteristic of companies still in the clinical development stage. The company holds $66.00M in cash against a debt obligation of $112,064, resulting in a Debt to Equity ratio of 0.18. This balance sheet structure is relatively conservative for the sector given the low debt load, though the negative cash flow suggests reliance on external capital markets to fund operations. The Current Ratio stands at 8.52, indicating a very strong short-term liquidity position where current assets significantly exceed current liabilities. Return on Equity is -46.4% and Return on Assets is -29.8%, metrics that reveal management is currently generating negative returns on the capital deployed, reflecting the inherent risk and high investment requirements of the biotechnology industry.
मूल्यांकन आकलन
The valuation metrics present a complex picture, with a Trailing P/E Ratio (TTM) listed as N/A due to the net loss, while the Forward P/E is reported as -5.60, implying that the market expects earnings to remain negative or for the loss to widen in the immediate future. The Price to Book ratio is 3.94, indicating that the market values the company at nearly four times its tangible book value, which suggests a premium placed on the intellectual property and clinical potential of the pipeline rather than current assets. The Price to Sales ratio is N/A as there is no reported revenue, and the EV/EBITDA stands at -4.34, further confirming that traditional earnings-based valuation multiples are not applicable at this stage of development. The stock has a 52-Week High of $3.62 and a 52-Week Low of $0.49, placing the current trading price within a volatile range typical for small-cap biotechnology stocks. The Beta value is 1.83, which indicates that the stock price is significantly more volatile than the broader market, moving with greater intensity than the S&P 500 during periods of market stress or rally. These alternative valuation metrics suggest that investors are pricing in future success based on clinical trial outcomes rather than current financial performance or sales figures.
Growth & Income
The available data lists Revenue Growth (YoY) and Earnings Growth (YoY) as N/A, as the company has not yet established a consistent revenue stream to calculate year-over-year growth rates. Consequently, there is no historical data to determine whether earnings are growing faster or slower than revenue, as both metrics are currently non-existent. Context Therapeutics Inc. does not pay dividends, evidenced by a Dividend Yield of N/A and a Payout Ratio of 0.0%, meaning the company retains all of its limited resources to fund research, development, and operational expenses rather than distributing income to shareholders. This reinvestment strategy is standard for biotechnology companies that prioritize clinical advancement and regulatory approval over returning capital to investors in the short term. The overall growth and income profile is characterized by zero current income and undefined growth rates, reflecting a business model entirely dependent on future commercialization of its anti-Claudin 6 x anti-CD3 bispecific antibody candidate.